Literature DB >> 27122976

A first look at relative survival by stage for colorectal and lung cancers in Canada.

J Chadder1, R Dewar2, L Shack3, D Nishri4, J Niu1, G Lockwood1.   

Abstract

Monitoring and reporting on cancer survival provides a mechanism for understanding the effectiveness of Canada's cancer care system. Although 5-year relative survival for colorectal cancer and lung cancer has been previously reported, only recently has pan-Canadian relative survival by stage been analyzed using comprehensive registry data. This article presents a first look at 2-year relative survival by stage for colorectal and lung cancer across 9 provinces. As expected, 2-year age-standardized relative survival ratios (arsrs) for colorectal cancer and lung cancer were higher when the cancer was diagnosed at an earlier stage. The arsrs for stage i colorectal cancer ranged from 92.2% in Nova Scotia [95% confidence interval (ci): 88.6% to 95.1%] to 98.4% in British Columbia (95% ci: 96.2% to 99.3%); for stage iv, they ranged from 24.3% in Prince Edward Island (95% ci: 15.2% to 34.4%) to 38.8% in New Brunswick (95% ci: 33.3% to 44.2%). The arsrs for stage i lung cancer ranged from 66.5% in Prince Edward Island (95% ci: 54.5% to 76.5%) to 84.8% in Ontario (95% ci: 83.5% to 86.0%). By contrast, arsrs for stage iv lung cancer ranged from 7.6% in Manitoba (95% ci: 5.8% to 9.7%) to 13.2% in British Columbia (95% ci: 11.8% to 14.6%). The available stage data are too recent to allow for meaningful comparisons between provinces, but over time, analyzing relative survival by stage can provide further insight into the known differences in 5-year relative survival. As the data mature, they will enable an assessment of the extent to which interprovincial differences in relative survival are influenced by differences in stage distribution or treatment effectiveness (or both), permitting targeted measures to improve population health outcomes to be implemented.

Entities:  

Keywords:  Lung cancer; colorectal cancer; relative survival by stage

Year:  2016        PMID: 27122976      PMCID: PMC4835006          DOI: 10.3747/co.23.3096

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  6 in total

1.  Comorbidity and Survival in Lung Cancer Patients.

Authors:  K M Monirul Islam; Xiaqing Jiang; Trisari Anggondowati; Ge Lin; Apar Kishor Ganti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-11       Impact factor: 4.254

2.  Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007.

Authors:  Camille Maringe; Sarah Walters; Bernard Rachet; John Butler; Tony Fields; Paul Finan; Roy Maxwell; Bjørn Nedrebø; Lars Påhlman; Annika Sjövall; Allan Spigelman; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Eva Morris; Colleen E McGahan; Elizabeth Tracey; Donna Turner; Michael A Richards; Michel P Coleman
Journal:  Acta Oncol       Date:  2013-04-15       Impact factor: 4.089

3.  The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006--a population-based cohort study.

Authors:  Lene H Iversen; Mette Nørgaard; Jacob Jacobsen; Søren Laurberg; Henrik T Sørensen
Journal:  Dis Colon Rectum       Date:  2009-01       Impact factor: 4.585

4.  Standard cancer patient population for age standardising survival ratios.

Authors:  Isabella Corazziari; Mike Quinn; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2004-10       Impact factor: 9.162

5.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.

Authors:  M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards
Journal:  Lancet       Date:  2010-12-21       Impact factor: 79.321

6.  Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.

Authors:  Sarah Walters; Camille Maringe; Michel P Coleman; Michael D Peake; John Butler; Nicholas Young; Stefan Bergström; Louise Hanna; Erik Jakobsen; Karl Kölbeck; Stein Sundstrøm; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom Børge Johannesen; Karen M Linklater; Colleen E McGahan; John Steward; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet
Journal:  Thorax       Date:  2013-02-11       Impact factor: 9.139

  6 in total
  1 in total

Review 1.  Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome.

Authors:  Jean-François Haince; Philippe Joubert; Horacio Bach; Rashid Ahmed Bux; Paramjit S Tappia; Bram Ramjiawan
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.